NTQ2494
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 22, 2023
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
Metastases • New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology
1 to 1
Of
1
Go to page
1